Select Medical (SEM) Q2 2025: Inpatient Rehab Jumps 17% as Regulatory Pressure Hits Critical Illness Margins

2025-08-01 | By EarningsIQ Research

Select Medical’s Q2 2025 showcased robust inpatient rehab growth, but regulatory headwinds weighed heavily on its critical illness recovery segment, exposing sharp margin divergence. Management continues to deploy capital into bed expansions and outpatient upgrades, while persistent reimbursement cuts and outlier rule changes challenge critical illness profitability. Investors face a business model straddling high-growth rehab and structurally pressured long-term acute care, with regulatory risk now permanently embedded in the outlook.

Summary

• Inpatient Rehab Expansion Accelerates: Strong demand and new openings are fueling double-digit growth in the rehab segment.
• Critical Illness Margins Erode: Reimbursement changes and high-cost outlier rules continue to compress profitability in the critical illness division.
• Capital Deployment Remains Active: Share buybacks, dividends, and ongoing facility investments signal management’s commitment to shareholder returns despite regulatory uncertainty.

Performance Analysis

Select Medical’s diversified model—combining inpatient rehabilitation, outpatient therapy, and critical illness recovery—delivered mixed results in Q2. The inpatient rehab division stood out, with revenue up 17% and adjusted EBITDA up nearly 15%, though margin dipped slightly due to early-stage hospital ramp-up and occupancy at new sites. Outpatient rehab posted moderate revenue growth of 3.8%, driven entirely by volume gains, but Medicare fee schedule cuts offset commercial rate improvements, capping per-visit revenue at $100.

The critical illness recovery segment, heavily exposed to regulatory risk, saw a 1% revenue decline and a steep 22% EBITDA drop, as CMS’s high-cost outlier threshold and the 20% transmittal rule slashed reimbursement for high-acuity patients. Occupancy improved to 69%, but salary and benefit ratios ticked up, further pressuring margins.

• Segment Divergence Widens: Inpatient rehab now contributes a larger share of profit, while critical illness recovery faces structural headwinds.
• Cash Flow and Leverage Stable: Operating cash flow reached $110 million, with net leverage at 3.57x and $319 million undrawn on the revolver.
• Capital Returned to Shareholders: $85 million in buybacks and a steady dividend reinforce capital allocation discipline amid uncertainty.

The quarter revealed a company balancing high-velocity growth in rehab with persistent margin drag in critical illness, underlining the importance of regulatory developments and operational execution in each segment.

Executive Commentary

Strategic Positioning

1. Inpatient Rehab as Core Growth Engine

Inpatient rehabilitation hospitals, post-acute care facilities for recovering patients, have become SEM’s primary growth vector. The company is aggressively expanding capacity, with 382 new rehab beds and 30 critical illness beds planned through mid-2027, including new hospitals and key market expansions. Management’s joint venture model with regional health systems—such as UPMC and Cleveland Clinic—mitigates risk and accelerates network scale.

2. Outpatient Rehab Platform Optimization

Outpatient rehabilitation, clinics for physical and occupational therapy, is seeing incremental margin improvement as scheduling and system upgrades take hold across the 2,000-plus clinic network. Leadership expects operational enhancements and volume leverage to push EBITDA margins above 10% by next year, despite ongoing Medicare reimbursement headwinds.

3. Critical Illness Recovery Under Structural Pressure

Long-Term Acute Care Hospitals (LTCHs), serving high-acuity, complex patients, remain under regulatory siege from CMS reimbursement changes, especially the high-cost outlier threshold and 20% transmittal rule. SEM is engaging with regulators for relief, but the segment faces continued closures and margin compression. The company’s high case mix index, a measure of patient complexity, exposes it to outsized risk from these policy shifts.

4. Capital Allocation Balancing Growth and Return

Management is actively deploying capital across buybacks, dividends, facility expansion, and system upgrades. The $85 million buyback and ongoing dividend reflect confidence in the core business, while capex is being tightly managed ($180 to $200 million projected for the year) to support strategic growth areas without overextending leverage.

Key Considerations

SEM’s quarter highlights a business at a crossroads, with inpatient rehab momentum offset by critical illness regulatory drag. Investors must weigh the sustainability of each segment’s economics and the company’s ability to adapt its model to evolving policy and payer dynamics.

Key Considerations:

• Rehab Demand Outpaces Supply: Demographics and post-acute trends are driving robust demand for inpatient and outpatient rehab, supporting ongoing facility expansion.
• Regulatory Volatility Remains the Wildcard: Critical illness margins hinge on CMS rulemaking, with little near-term relief expected on the high-cost outlier pool or transmittal rules.
• Margin Mix Shifts Underway: Profitability is concentrating in rehab, while the critical illness business risks becoming a drag unless policy or payer mix improves.
• Labor Cost Environment Improving: Wage inflation in core facilities has moderated below 3%, and agency staffing costs have normalized post-pandemic, aiding margin recovery in rehab and outpatient.
• Capital Flexibility Maintained: Strong cash generation and ample revolver capacity provide SEM with optionality for both defensive and offensive capital deployment.

Risks

SEM’s exposure to regulatory risk in the critical illness recovery segment remains acute, with CMS reimbursement changes directly impacting margin and hospital viability. The unpredictability of future Medicare policy, ongoing Medicare Advantage denials, and the risk of further fee schedule cuts in outpatient rehab all pose material challenges. Growth in rehab beds could also pressure occupancy and ramp-up margins if market demand falters or competitive intensity rises.

Forward Outlook

For Q3 2025, Select Medical guided to:

• Continued strength in inpatient rehab revenue and margin expansion as new beds come online
• Ongoing outpatient margin improvement, targeting 10% EBITDA margin by early 2026

For full-year 2025, management reaffirmed guidance:

• Revenue: $5.3 billion to $5.5 billion
• Adjusted EBITDA: $510 million to $530 million
• Adjusted EPS: $1.09 to $1.19
• Capex: $180 million to $200 million

Management cited:

• Rehab outperformance offsetting critical illness shortfall in guidance mix
• Regulatory headwinds fully incorporated into outlook, with no upside assumed from potential policy relief

Takeaways

SEM’s results reinforce the business model’s bifurcation: inpatient rehab’s secular growth is offset by critical illness recovery’s regulatory fragility. Operational discipline and capital allocation provide a buffer, but margin risk is now structurally embedded in the portfolio.

• Rehab Drives Value Creation: Expansion and joint ventures underpin long-term growth, with operational leverage and demographic tailwinds favoring this segment.
• Policy Risk Caps Upside: Regulatory and reimbursement volatility in critical illness recovery constrain profitability and limit segment expansion.
• Watch for Occupancy and Margin Trends: Investors should monitor ramp-up performance in new rehab beds, outpatient system upgrades, and regulatory developments affecting the critical illness business.

Conclusion

Select Medical’s Q2 demonstrates a company leaning into its strengths in rehab while navigating persistent regulatory and reimbursement risk in critical illness recovery. The outlook is stable, but the margin mix will remain in flux as policy and payer trends evolve. Investors should expect continued capital returns, measured growth, and a vigilant stance on policy engagement.

Industry Read-Through

SEM’s experience highlights the acute sensitivity of post-acute and long-term acute care providers to CMS policy shifts and reimbursement volatility. The rapid contraction in the LTCH industry, driven by outlier rule changes and transmittal policies, foreshadows further consolidation and margin compression for peers. Conversely, the secular growth in inpatient rehab and outpatient therapy reflects demographic tailwinds and health system demand for post-acute capacity, supporting network expansion for operators with scale and capital flexibility. Investors in the healthcare facilities space should focus on payer mix, regulatory risk management, and the ability to shift capital toward higher-growth, less regulated care settings.

SEM Healthcare Post-Acute Care Rehabilitation Regulatory Margin Capital Allocation